First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia
Rea D et al. – Frontline imatinib allows favorable outcomes in HEM–accelerated–phase (AP) and ACA–AP patients but appears insufficient for patients with HEM–AP+ACA. Broader–target and/or more potent BCR–ABL tyrosine kinase inhibitors alone or in combination may be considered in this setting.
The authors evaluated the benefit of imatinib in 42 newly diagnosed AP-CML patients.
In all, 16 patients had hematological acceleration without chromosomal abnormalities in addition to the Philadelphia chromosome (ACAs; HEM-AP), 16 solely had ACAs (ACA-AP) and 10 had hematological acceleration plus ACAs (HEM-AP+ACA).
Major cytogenetic responses were achieved in 93.7% of HEM-AP patients, 75% of patients with ACA-AP (P=NS) and 40% of patients with HEM-AP+ACA (P=0.0053).
The 24-month failure-free survival rate was 87.5% in HEM-AP patients, 43.8% in ACA-AP patients and 15% in HEM-AP+ACA patients (P=0.022).
The 24-month estimate of progression-free survival was 100% in HEM-AP patients, 92.8% in ACA-AP patients and 58.3% in HEM-AP+ACA patients (P=0.0052).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.